Lucid Diagnostics Inc. (NASDAQ:LUCD) Short Interest Down 18.0% in April

Lucid Diagnostics Inc. (NASDAQ:LUCD) was the target of a significant decline in short interest during the month of April. As of April 15th, there was short interest totalling 361,400 shares, a decline of 18.0% from the March 31st total of 441,000 shares. Approximately 2.5% of the company’s stock are sold short. Based on an average daily trading volume, of 164,900 shares, the short-interest ratio is presently 2.2 days.

Lucid Diagnostics Stock Up 9.9 %

Lucid Diagnostics stock traded up $0.07 during midday trading on Monday, reaching $0.75. 275,079 shares of the stock traded hands, compared to its average volume of 146,250. The stock’s fifty day moving average is $1.02 and its 200-day moving average is $1.24. Lucid Diagnostics has a 12 month low of $0.63 and a 12 month high of $1.85. The stock has a market cap of $36.21 million, a P/E ratio of -0.59 and a beta of 1.63.

Lucid Diagnostics (NASDAQ:LUCD) last issued its quarterly earnings results on Tuesday, March 26th. The company reported ($0.26) earnings per share for the quarter. The business had revenue of $1.04 million during the quarter. Lucid Diagnostics had a negative return on equity of 901.79% and a negative net margin of 2,169.07%. During the same quarter last year, the firm posted ($0.22) EPS. On average, equities analysts predict that Lucid Diagnostics will post -0.92 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research analysts have recently weighed in on the company. Cantor Fitzgerald decreased their price target on Lucid Diagnostics from $3.80 to $3.00 and set an “overweight” rating for the company in a research note on Wednesday, March 27th. Needham & Company LLC reissued a “buy” rating and set a $2.50 price target on shares of Lucid Diagnostics in a report on Friday, April 12th.

Lucid Diagnostics Company Profile

Lucid Diagnostics Inc, a commercial-stage medical diagnostics technology company, focuses on patients with gastroesophageal reflux disease who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma in the United States. The company's flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths through early detection of esophageal precancer in at-risk GERD patients.